Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma

NCT00131937 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Hepatosplenic T-cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

Interventions

DRUG: sorafenib tosylate

Sponsor

National Cancer Institute (NCI)